ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2748

Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk

Elena Pachera1, Shervin Assassi 2, Gloria Salazar 3, Mojca Frank-Bertoncelj 4, Jörg Distler 5, Gabriela Kania 6 and Oliver Distler 7, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Zurich, Switzerland, 2Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 3University of Texas McGovern Medical School, Houston, 4University Hospital Zürich, Zürich, Switzerland, 5Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 6Centre of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 7Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fibrosis, RNA and tissue growth factor (TGF), Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T095: Systemic Sclerosis & Related Disorder – Basic Science (2744–2749)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Long noncoding RNAs (lncRNAs) are an emerging class of noncoding transcripts involved in the regulation of gene expression in health and disease. LncRNAs function via different mechanisms either acting cis, regulating the expression of nearby genes, or in trans, modulating the expression of distant genes. We have identified a novel TGFβ regulated lncRNA, H19X, which was strongly and consistently upregulated in a wide variety of fibrotic disorders. Moreover, we were able to demonstrate that H19X is a key driver of myofibroblast formation and extracellular matrix (ECM) overproduction. Here we aimed to define the mode of action of H19X and to assess H19X functions that may drive myofibroblast differentiation and ECM production.

Methods: The function of H19X was investigated in SSc dermal fibroblasts (n=5) by knocking down H19X with locked nucleic acid oligonucleotides (LNA GapmeRs) followed by TGF-β stimulation and microarray analysis with Illumina HT-12 arrays. In situ hybridization for H19X was performed using Stellaris FISH probes. Genomic regions of interaction with H19X were identified by Chromatin Isolation by RNA Purification (ChIRP) using biotinylated probes tiling the transcript, RNA pull-down and sequencing. Chromatin remodeling was investigated by Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq). DNA damage-inducible transcript 4-like protein (DDIT4L) function was tested using siRNA in parallel to H19X downregualtion.

Results: As analyzed by microarray, none of the 16 genes belonging to the same genomic region (1 Mb) as H19X locus was affected by its downregulation, indicating that in-cis regulation is not a major mechanism of H19X activity. Cellular localization can give a first indication about lncRNA trans function: FISH staining of SSc fibroblasts stimulated with TGF-β revealed tightly localized nuclear foci in TGF-β treated cells. Moreover, increased numbers of positive nuclei were also recorded after TGF-β stimulation. H19X nuclear localization was confirmed by cell fractionation, where H19X expression was peaking in the nucleus of cells after 6h of treatment with TGF-β.
 
Next, we identified 58 genomic regions that directly interact with H19X using ChIRP. In order to establish the effect of H19X physical presence at these sites, the expression of the genes with the closest transcription start site was analyzed in the microarray data set. Among these genes, DDIT4L displayed the strongest induction following H19X knockdown. Furthermore, we cloud identify chromatin rearrangements caused by H19X knockdown in close proximity with its interaction site with DDIT4L locus using ATAC-seq. Interestingly, DDIT4L expression was consistently repressed by TGFβ stimulation at mRNA and protein level. Additionally, DDIT4L knockdown was able to restore COL1A1 expression that was reduced by H19X downregulation but only in presence of TGFβ. These data indicate that H19X mediates its effects unabeling DDIT4L transcription which, in turn, is a novel repressor of TGFβ pathway activity.

Conclusion: Our data uncover a novel mechanism for the TGFβ regulated profibrotic effects of H19X including direct effects on chromatin organization associated with fibrotic pathways.


Disclosure: E. Pachera, None; S. Assassi, Bayer, 2, Boehringer Ingelheim, 2, 5, 8, Integrity Continuing Education, 8, 9, Medscape, 8, 9, Momenta, 2; G. Salazar, None; M. Frank-Bertoncelj, Kurt und Senta Herrmann Foundation, 2, Promedica Foundation, 2; J. Distler, 4D Science, 4, Actelion, 5, Actelion Pharmaceuticals, 5, Active Biotech, 2, 5, AnaMar, 2, 5, Array Biopharma, 2, aTyr, 2, Bayer, 2, 5, BMS, 2, Boehringer Ingelheim, 2, 5, Bristol-Myers Squibb, 2, Celgene, 2, 5, Galapagos, 2, 5, GlaxoSmithKline, 2, 5, Inventiva, 2, 5, JB Therapeutics, 5, medac, 5, Medac, 5, Novartis, 2, Pfizer, 5, RedX, 2, RuiYi, 5, Sanofi, 2, Sanofi-Aventis, 2, UCB, 2, 5; G. Kania, Bayer, 2, Actelion, 8, Boehringer Ingelheim, 8; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5.

To cite this abstract in AMA style:

Pachera E, Assassi S, Salazar G, Frank-Bertoncelj M, Distler J, Kania G, Distler O. Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cracking-a-novel-profibrotic-molecular-mechanism-lncrna-h19x-and-ddit4l-crosstalk/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cracking-a-novel-profibrotic-molecular-mechanism-lncrna-h19x-and-ddit4l-crosstalk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology